Comparing toxicity profiles for 72 hour infusional and conventional bleomycin in testicular cancer
Comparing toxicity profiles for 72 hour infusional and conventional bleomycin in testicular cancer
UK fight for tobacco control
Engineering of polymeric nanoparticles for medical applications
Editor’s Choice - ecancermedicalscience November 2013
The immune microenvironment as an anti-cancer therapeutic strategy
Choosing the right treatment for each patient: The emergence of personalised healthcare in non-small cell lung cancer
The revolution in personalised healthcare: Towards improved outcomes in oncology: Conclusion and Summary
Brain mestastases from lung cancer ECC 2013
European Cancer Congress 2013 - News Roundup
New antibody drug, MPDL3280A, in non-small cell lung cancer
Comment on immunotherapy in lung cancer from the ECC 2013 Scientific Co-Chair
Results for new antibody drug in non-small cell lung cancer